Menu
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

bluebird bio, Inc. - Common Stock (NQ:BLUE)

4.970 UNCHANGED
Last Price Updated: 4:00 PM EDT, May 30, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about bluebird bio, Inc. - Common Stock

< Previous 1 2
...
16 17 18 19 20 21 22 23 Next >
News headline image
The Week Ahead In Biotech (Dec. 12-18): Hematology Conference Presentations, FDA Decisions For Calliditas, Argenx, Intra-Cellular & Eagle Pharma And More ↗
Biotech stocks closed out the week ending Dec. 10 with modest losses as investors moved money out of defensives and into risky bets amid the broader market rebound. Multiple... 
Via Benzinga
News headline image
New Data at ASH21, Published in NEJM Further Demonstrate beti-cel as a Potentially Curative One-Time Gene Therapy for β-thalassemia Patients Who Require Regular Transfusions Through Achievement of Durable TI and Normal or Near-Normal Adult Hb Levels
From bluebird bio, Inc.
Via Business Wire
News headline image
12 Health Care Stocks Moving In Monday's Pre-Market Session ↗
Gainers iSpecimen (NASDAQ:ISPC) stock rose 31.09% to $6.45 during Monday's pre-market session. The company's market cap stands at $44.9 million. Provention Bio (... 
Via Benzinga
News headline image
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday ↗
Welcome back, traders! We're getting right into the week with a breakdown of the biggest pre-market stock movers for Monday! 
Via InvestorPlace
News headline image
Bluebird Bio's Thalassemia Gene Therapy Under Priority Review With FDA ↗
The FDA has accepted Bluebird bio Inc's (NASDAQ: BLUE) marketing application for betibeglogene autotemcel (beti-cel) for β-thalassemia. The agency has... 
Via Benzinga
News headline image
bluebird bio Announces FDA Priority Review of Biologics License Application for beti-cel Gene Therapy for Patients with β-thalassemia Who Require Regular Red Blood Cell Transfusions
From bluebird bio, Inc.
Via Business Wire
News headline image
64 Biggest Movers From Yesterday ↗
Gainers Pioneer Power Solutions, Inc. (NASDAQ: PPSI) shares jumped 219% to close at $10.40 on Monday after the company announced the launch of its E-Boost portfolio of mobile... 
Via Benzinga
News headline image
Why Bluebird Bio Stock Plunged Today ↗
Two analysts downgraded the biotech stock. 
Via The Motley Fool
News headline image
Market Rally Continues as Dow Nabs Intraday Highs ↗
S&P 500 Index and Nasdaq Composite are sporting modest gains, with the Dow locking in another fresh intraday high. 
Via Talk Markets
Topics Stocks
News headline image
38 Stocks Moving In Monday's Mid-Day Session ↗
Gainers Pioneer Power Solutions, Inc. (NASDAQ: PPSI) shares climbed 129.8% to $7.49 after the company announced the launch of its E-Boost portfolio of mobile Electric Vehicle... 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Monday's Intraday Session ↗
Gainers PetVivo Holdings (NASDAQ:PETV) s... 
Via Benzinga
News headline image
Benzinga's Top Ratings Upgrades, Downgrades For November 8, 2021 ↗
Upgrades For Nektar Therapeutics (NASDAQ: 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Friday's Intraday Session ↗
Gainers Chinook Therapeutics (NASDAQ:KDNY) shares increased by 28.75% to $15.76 during Friday's regular session. Trading volume for this security as of 12:30 EST is 1.... 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Friday's Pre-Market Session ↗
Gainers Ontrak (NASDAQ:OTRK) shares rose 21.82% to $11.78 during Friday's pre-market session. The market value of their outstanding shares is at $225.5 million. As per... 
Via Benzinga
News headline image
92 Biggest Movers From Friday ↗
Gainers Mainz Biomed B.V. (NASDAQ: MYNZ) shares jumped 99.8% to close at $9.99 on Friday. Mainz Biomed priced its initial public offering of 2 million ordinary shares at $5, the... 
Via Benzinga
News headline image
64 Stocks Moving In Friday's Mid-Day Session ↗
Gainers Mainz Biomed B.V. (NASDAQ: MYNZ) shares climbed 198.4% to $14.92. Mainz Biomed priced its initial public offering of 2 million ordinary shares at $5, the middle of the... 
Via Benzinga
News headline image
bluebird bio Reports Third Quarter Financial Results and Recent Operational Progress
From bluebird bio, Inc.
Via Business Wire
News headline image
bluebird bio and Federal Realty to Establish Biotech Footprint at Assembly Row
From bluebird bio, Inc.
Via Business Wire
News headline image
28 Stocks Moving in Friday's Pre-Market Session ↗
Gainers ReWalk Robotics Ltd. (NASDAQ: RWLK) rose 65.8% to $2.14 in pre-market trading after the company announced its ReBoot device has been granted designation as a Breakthrough... 
Via Benzinga
News headline image
bluebird bio to Present New Gene Therapy Data at the 63rd American Society of Hematology (ASH) Annual Meeting and Exposition
From bluebird bio, Inc
Via Business Wire
News headline image
bluebird bio Completes Planned Business Separation
From bluebird bio, Inc.
Via Business Wire
News headline image
Bluebird Bio To Withdraw Marketing Of Skysona Gene Therapy In Europe ↗
Bluebird Bio Inc (NASDAQ: BLUE) will withdraw the regulatory marketing authorization for Skysona (elivaldogene autotemcel) in the European Union. The update comes... 
Via Benzinga
News headline image
Could This Beaten-Down Biotech Stock Be the Next Buyout Target? ↗
This gene-therapy specialist may need some help turning things around. 
Via The Motley Fool
News headline image
bluebird bio Sets Record Date and Distribution Date for Planned Business Separation
From bluebird bio, Inc.
Via Business Wire
News headline image
Bluebird Bio or Heron Therapeutics: Which Stock Is the Better Comeback Play? ↗
These once-promising biotech stocks are trading at a fraction of their all-time highs right now. 
Via The Motley Fool
News headline image
bluebird bio Provides Update on Upcoming Planned Business Separation
From bluebird bio, Inc.
Via Business Wire
News headline image
Bluebird Bio Files US Application For β-thalassemia Gene Therapy ↗
Bluebird Bio Inc (NASDAQ: BLUE) completed the rolling submission of its marketing application to the FDA seeking approval for betibeglogene autotemcel (beti-cel)... 
Via Benzinga
News headline image
bluebird bio Submits Biologics License Application (BLA) to FDA for betibeglogene autotemcel (beti-cel) Gene Therapy for Patients With β-thalassemia Who Require Regular Red Blood Cell Transfusions
From bluebird bio, Inc.
Via Business Wire
News headline image
The Daily Biotech Pulse: Pfizer-BioNTech US Vaccine Contract, Summit Slumps On Adverse Regulatory Feedback, Cerevel CFO Departs ↗
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 20) Acceleron Pharma Inc. (... 
Via Benzinga
News headline image
2seventy bio Announces Upcoming Investor Events
From bluebird bio
Via Business Wire
< Previous 1 2
...
16 17 18 19 20 21 22 23 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.